Welcome to our dedicated page for NeuroOne Medical Technologies Corporation news (Ticker: NMTC), a resource for investors and traders seeking the latest updates and insights on NeuroOne Medical Technologies Corporation stock.
NeuroOne Medical Technologies Corporation (symbol: NMTC) is a cutting-edge medical technology company based in Eden Prairie, Minnesota. The company specializes in the development and commercialization of innovative thin-film electrode technology designed for continuous electroencephalogram (cEEG) and stereoelectroencephalography (sEEG) recording, brain stimulation, and ablation solutions. These technologies are particularly beneficial for patients suffering from a variety of brain-related disorders, including epilepsy, Parkinson's disease, dystonia, and essential tremors.
NeuroOne's core business revolves around creating comprehensive neuromodulation solutions that integrate cEEG and sEEG recording, monitoring, brain stimulation, and ablation. This focus has led to notable advancements such as the Evo® sEEG system, which is the first FDA-cleared thin-film sEEG-guided RF system capable of both recording electrical activity and ablating nervous tissue, with the added benefit of temperature control.
The company is actively involved in various exciting projects and partnerships. One of their key initiatives is the Drug Delivery Program, which is expected to achieve several important milestones in the near future. Additionally, NeuroOne is continuously enhancing its product portfolio to better serve its target patient population.
Financially, NeuroOne has provided promising updates for the second quarter of the fiscal year 2024. The company’s recent business highlights include significant progress in their OneRF™ Ablation System and Spinal Cord Stimulation Program. Investors and interested parties can access more detailed financial results and updates through their quarterly conference calls and webcasts.
For more information or to get in touch with NeuroOne, please contact them at 800-631-4030 or email ir@nmtc1.com.
NeuroOne Medical Technologies Corp. (NASDAQ:NMTC) is advancing minimally invasive surgery (MIS) technology to improve patient outcomes and reduce costs. The MIS market is projected to grow at a 10.4% CAGR, reaching $70 billion by 2030, driven by chronic disease prevalence and advancements in medical imaging and robotic surgery.
NeuroOne focuses on innovative solutions for neurological disorders, including its OneRF® Ablation system, which promises enhanced accuracy and lower risks. Their recent success in animal implants of a novel thin film paddle lead for spinal cord stimulation marks a significant step in reducing surgical invasiveness.
With a partnership with Zimmer Biomet Holdings for diagnostic applications and plans for regulatory submission, NeuroOne is positioned to capture significant market opportunities in the growing MIS sector.
NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) has achieved a significant milestone by successfully completing an initial animal implant of its innovative thin film paddle leads for spinal cord stimulation. This advancement aims to treat chronic back pain associated with multiple failed back surgeries and intractable pain in the lower back and legs. The animal study confirmed the feasibility of the devices, ensuring they could be easily placed within the epidural space. Additionally, the company is developing a percutaneous delivery system to streamline the implantation process. CEO Dave Rosa highlighted the large market potential, emphasizing improved patient outcomes and device efficiency.
NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) will participate in the 35th Annual Roth Conference from March 12-14, 2023, in Dana Point, California. CEO Dave Rosa will hold one-on-one meetings with institutional investors and analysts on March 13th and 14th. The conference will take place at The Ritz Carlton, Laguna Niguel. Investors can register through the conference website or contact a Roth representative at 800.678.9147. NeuroOne focuses on developing minimally invasive solutions for neurological disorders, aiming to improve patient outcomes and reduce healthcare costs.
NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) announced the award of a new patent for its innovative thin film neural depth electrode technology. The patent, titled "Improved Neural Depth Probes and Related Systems and Methods," enhances the company's intellectual property portfolio, which now includes three licensed patents, eight pending applications in the U.S., and several foreign applications.
This technology aims to improve surgical outcomes for various neurological disorders, including epilepsy and Parkinson's disease. CEO Dave Rosa emphasized the company's commitment to advancing its electrode technology and securing its proprietary methods.
NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) reported its fiscal first quarter 2023 results, highlighting significant advancements in its product offerings. The company received FDA 510(k) clearance for its Evo® sEEG Electrode technology, addressing a $100M market. Product revenue climbed to $115,000 from $34,000 in Q1 2022, while collaboration revenue surged to $1.46 million from $6,000. Operating expenses increased to $3.2 million, with a net loss of $1.7 million, an improvement from a $2.8 million loss a year earlier. Cash reserves decreased to $7.6 million, down from $11.1 million. The firm aims for a commercial launch with Zimmer Biomet and plans to submit the OneRF system for FDA clearance in 2023.
NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) will host a conference call on February 14, 2023, at 4:30 PM ET, to discuss its financial results for the fiscal first quarter 2023, ending December 31, 2022. The call will also include a corporate update. Interested parties can join the call via dial-in at 877-405-1216 or through a live webcast here. NeuroOne specializes in minimally invasive solutions for neurological disorders, aiming to enhance surgical care and reduce costs.
NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) reported its fiscal year 2022 achievements and outlined key catalysts for 2023 in a Winter Letter to Shareholders. CEO Dave Rosa highlighted the launch of their Evo® sEEG diagnostic line in partnership with Zimmer Biomet, as well as an FDA 510(k) submission for a combination diagnostic and ablation electrode system. The company aims to enhance patient outcomes in neurological treatments. NeuroOne's focus remains on disruptive technology developed in collaboration with medical experts, anticipating a productive year ahead for stakeholders.
NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) reported its fiscal fourth quarter and full year 2022 results, showing product revenue of $69,000 for Q4 and $171,000 for the full year, with a slight decline from the previous year. Collaboration revenue saw a significant increase to $1,942,000 in Q4 and $1,949,000 for the year, driven by the Zimmer Development Agreement. Despite higher operating expenses totaling $3.3 million in Q4, the net loss narrowed to $1.4 million compared to $2.6 million in the previous year. The company ended the year with $11.1 million in cash and no debt.
FAQ
What is the current stock price of NeuroOne Medical Technologies Corporation (NMTC)?
What is the market cap of NeuroOne Medical Technologies Corporation (NMTC)?
What does NeuroOne Medical Technologies Corporation focus on?
Where is NeuroOne Medical Technologies Corporation based?
What disorders does NeuroOne's technology address?
What is the Evo® sEEG system?
What are some of NeuroOne's current projects?
How can I contact NeuroOne Medical Technologies Corporation?
What recent financial updates has NeuroOne provided?
What type of medical technology does NeuroOne specialize in?
What is the significance of the FDA clearance for NeuroOne's technology?
Where can I find more detailed financial results and updates about NeuroOne?
